Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada
- DOI
- Language of the publication
- English
- Date
- 2023-10-01
- Type
- Article
- Author(s)
- Costiniuk, Cecilia T.
- Singer, Joel
- Lee, Terry
- Galipeau, Yannick
- McCluskie, Pauline S.
- Arnold, Corey
- Langlois, Marc-André
- Needham, Judy
- Jenabian, Mohammad-Ali
- Burchell, Ann N.
- Samji, Hasina
- Chambers, Catharine
- Walmsley, Sharon
- Ostrowski, Mario
- Kovacs, Colin
- Tan, Darrell H. S.
- Harris, Marianne
- Hull, Mark
- Brumme, Zabrina L.
- Lapointe, Hope R.
- Vulesevic, Branka
- Brockman, Mark A.
- Margolese, Shari
- Mandarino, Enrico
- Samarani, Suzanne
- Lebouché, Bertrand
- Angel, Jonathan B.
- Routy, Jean-Pierre
- Cooper, Curtis L.
- Anis, Aslam H.
- COVAXHIV Study Group
- Publisher
- Wolters Kluwer Health, Inc.
Abstract
Objectives: Many vaccines require higher/additional doses or adjuvants to provide adequate protection for people with HIV (PWH). Here, we compare coronavirus disease 2019 (COVID-19) vaccine-induced antibody neutralization capacity in PWH vs. HIV-negative individuals following two vaccine doses. Design: In Canadian prospective observational cohorts, including a multicentre study of PWH receiving at least two COVID-19 vaccinations (mRNA or ChAdOx1-S), and a parallel study of HIV-negative controls (Stop the Spread Ottawa Cohort), we measured vaccine-induced neutralization capacity 3 months post dose 2 (±1 month). Methods: COVID-19 neutralization efficiency was measured by calculating the half maximal inhibitory dilution (ID50) using a high-throughput protein-based neutralization assay for Ancestral (Wuhan), Delta and Omicron (BA.1) spike variants. Univariable and multivariable quantile regression were used to compare COVID-19-specific antibody neutralization capacity by HIV status. Results: Neutralization assays were performed on 256 PWH and 256 controls based on specimen availability at the timepoint of interest, having received two vaccines and known date of vaccination. There was a significant interaction between HIV status and previous COVID-19 infection status in median ID50. There were no differences in median ID50 for HIV+ vs. HIV-negative persons without past COVID-19 infection. For participants with past COVID-19 infection, median ICD50 was significantly higher in controls than in PWH for ancestral SARS-CoV-2 and Omicron variants, with a trend for the Delta variant in the same direction. Conclusion: Vaccine-induced SARS-CoV-2 neutralization capacity was similar between PWH vs. HIV-negative persons without past COVID-19 infection, demonstrating favourable humoral-mediated immunogenicity. Both HIV+ and HIV-negative persons demonstrated hybrid immunity.
Subject
- Health,
- Coronavirus diseases
Rights
Pagination
F25-F35
Peer review
Yes
Open access level
Gold
Identifiers
- PubMed ID
- 37534695
- ISSN
- 0269-9370
Article
- Journal title
- AIDS
- Journal volume
- 37
- Journal issue
- 12
Sponsors
This project was supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force (grant number: 2122-HQ-000075) and the CTN (grant number: N/A). Production of COVID-19 reagents was financially supported by NRC's Pandemic Response Challenge Program.